Clinical Trials Directory

Trials / Unknown

UnknownNCT03553238

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
Nanfang Hospital, Southern Medical University · Academic / Other
Sex
All
Age
14 Years – 55 Years
Healthy volunteers
Not accepted

Summary

ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial is aimed to evaluate the safety and effect of a novel oral histone deacetylase inhibitor chidamide for adult ETP-ALL/LBL in CHINA.

Detailed description

Early T-cell precursor (ETP) lymphoblastic leukemia (ETP-ALL) is a neoplasm composed of cells committed to the T-cell lineage but with an unique immunophenotype indicating only limited early T differentiation. In the highly orchestrated development of T cell fate specification under physiological condition, the most immature early thymic progenitors (ETPs) retain multilineage potentials. ETP-ALL blasts have a characteristic immunophenotype, with reduced/absent expression of T-lymphoid markers CD1a, CD5, CD8; and positivity for at least one HSC and/or myeloid antigen CD34, CD117, HLA-DR, CD13, CD33, CD11b, CD65. Recent study shed light on the genetic landscape of adult ETP-ALL, which revealed that more than 40% adult ETP-ALL harbored histone modification mutations. Chidamide is a novel oral HDACi with promising activity in non-Hodgkin lymphoma (NHL). Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial is aimed to evaluate the safety and effect of a novel oral histone deacetylase inhibitor chidamide for adult ETP-ALL/LBL. HDACi chidamide at a dose of 10mg/day will be added to ETP-ALL group from induction therapy to consolidation therapy (total courses of chidamide treatment: 5 courses for allo-HSCT after Consolidation Module-3; 12 courses for patients non-allo-HSCT after Consolidation Module 1-9). Primary study endpoint of PDT-ETP-ALL is event-free survival of ETP-ALL group and secondary study endpoints are complete remission and MRD after induction, adverse event and overall survival of ETP-ALL group. Pretreatment: Dexamethasone, -3 to 0d; Induction:VCR: 1, 8, 15, 22; IDA: 1, 8; CTX: 1g/m2, 1, 8; PEG-asp: 2000-2500IU/m2, 1, 15; Dex: 1-24, chidamide: 10mg/d, po, qd. MRD: d14, 24, 45, and pre-allo-HSCT. VLCAM (MRD1/d14\>1%): CTX, d25; AraC 2g/m2, q12h, d25, 26; 6-MP: 25-31, PEG-asp: 26; chidamide: 10mg/d, po, qd. Consolidation Module: CM-1: AraC 3g/m2, q12h, 1-2, Dex: 10mg/m2, 1-2, PEG-asp: 2, 6-MP: 1-7. IT: d1, chidamide: 10mg/d, po, qd. CM-2: MTX 5g/m2, 1, Dex: 10mg/m2, 1-2, PEG-asp: 2; 6-MP: 1-7; IT: d1; chidamide: 10mg/d, po, qd. CM-3: CTX 0.5g/m2, 1-3, PEG-asp: 2, Doxorubicin: 40mg/m2, 4, 6-MP: 1-7, IT: d1;chidamide: 10mg/d, po, qd. Allo-HSCT: after CM-3 when donors available. Non-HSCT: finish CM 4-9 and POMP maintenance. CM 4-6: repeat CM 1-3. Re-Induction: after CM-6. CM 7-9: repeat CM1-3. Maintenance: CPOMP-chidamide 10mg/d, po, qd; Pred for 12 months; VCR for 12 months; MTX for 24 months; 6-MP for 24 months.

Conditions

Interventions

TypeNameDescription
DRUGChidamideChidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
DRUGDexamethasoneDexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
DRUGvincristineVincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
DRUGCyclophosphamideCTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
DRUGIdarubicinIDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
DRUGPegaspargasePEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
DRUGAdriamycinAdriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
DRUGMethotrexateMethotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
DRUG6-MercaptopurineMercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
DRUGEtoposideVP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
DRUGCytarabineAraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
PROCEDUREBone marrow aspirationBone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
PROCEDUREIntrathecal injectionIntrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
RADIATIONRadiation therapyRadiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
GENETICNGSNext-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
PROCEDUREallogeneic hematopoietic stem cell transplantationAllo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
DIAGNOSTIC_TESTFlow-MRDFlow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
DIAGNOSTIC_TESTFISHFISH will be performed in PDT-ETP-ALL for bone marrow samples.
DIAGNOSTIC_TESTFlow immunophenotypingFlow immunophenotyping will be performed in PDT-ETP-ALL protocol.
DIAGNOSTIC_TESTKaryotypingKaryotyping will be performed in PDT-ETP-ALL protocol.

Timeline

Start date
2016-02-14
Primary completion
2020-05-30
Completion
2020-08-30
First posted
2018-06-12
Last updated
2018-06-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03553238. Inclusion in this directory is not an endorsement.